Q2 FY2022 · ended Jun 30, 2022 · Revenue $0 · Filed Aug 22, 2022
MAIA Biotechnology, Inc. (MAIA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$0
Net income
$-7.94M
-48.6% vs year-ago quarter
Operating cash flow
$-6.75M
-63.2% vs year-ago quarter
Free cash flow
—
EPS
$-0.13
+27.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
60.83M
+84.4% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MAIA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1878313
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$8.3M | -$6.9M | -$4.3M | -$9.4M | -$5.2M |
| Net income | -$7.9M | -$6.4M | -$3.6M | -$8.9M | -$5.3M |
| Diluted EPS | -$0.13 | -$0.14 | -$0.10 | -$0.27 | -$0.18 |
| Operating cash flow | -$6.8M | -$5.3M | -$7.0M | -$3.5M | -$4.1M |
| Total assets | $28.2M | $35.3M | $9.7M | $11.8M | $11.0M |
| Total liabilities | $7.6M | $7.6M | $7.3M | $11.7M | $7.2M |
| Stockholders' equity | $20.7M | $27.8M | $2.4M | $41,670 | $3.9M |
| Cash and investments | $0 | $0 | $0 | $0 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 6, 2026 | Oct 6, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
| 8-K |
Current report
Agreement ended
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 16, 2026 | Apr 16, 2026 |
All 503 MAIA Biotechnology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.